Nancy E Moran1, Morgan J Cichon2, Kenneth M Riedl3, Elizabeth M Grainger1, Steven J Schwartz3, Janet A Novotny4, John W Erdman5, Steven K Clinton6. 1. The Ohio State University Comprehensive Cancer Center. 2. Departments of Food Science and Technology. 3. The Ohio State University Comprehensive Cancer Center, Departments of Food Science and Technology. 4. Human Nutrition Research Center, USDA, Beltsville, MD; and. 5. Department of Food Science and Human Nutrition and Division of Nutritional Sciences, The University of Illinois, Urbana, IL. 6. The Ohio State University Comprehensive Cancer Center, Internal Medicine-Division of Medical Oncology, and The James Cancer Hospital, The Ohio State University, Columbus, OH; steven.clinton@osumc.edu.
Abstract
BACKGROUND: Lycopene, which is a red carotenoid in tomatoes, has been hypothesized to mediate disease-preventive effects associated with tomato consumption. Lycopene is consumed primarily as the all-trans geometric isomer in foods, whereas human plasma and tissues show greater proportions of cis isomers. OBJECTIVE: With the use of compartmental modeling and stable isotope technology, we determined whether endogenous all-trans-to-cis-lycopene isomerization or isomeric-bioavailability differences underlie the greater proportion of lycopene cis isomers in human tissues than in tomato foods. DESIGN: Healthy men (n = 4) and women (n = 4) consumed (13)C-lycopene (10.2 mg; 82% all-trans and 18% cis), and plasma was collected over 28 d. Unlabeled and (13)C-labeled total lycopene and lycopene-isomer plasma concentrations, which were measured with the use of high-performance liquid chromatography-mass spectrometry, were fit to a 7-compartment model. RESULTS: Subjects absorbed a mean ± SEM of 23% ± 6% of the lycopene. The proportion of plasma cis-(13)C-lycopene isomers increased over time, and all-trans had a shorter half-life than that of cis isomers (5.3 ± 0.3 and 8.8 ± 0.6 d, respectively; P < 0.001) and an earlier time to reach maximal plasma concentration than that of cis isomers (28 ± 7 and 48 ± 9 h, respectively). A compartmental model that allowed for interindividual differences in cis- and all-trans-lycopene bioavailability and endogenous trans-to-cis-lycopene isomerization was predictive of plasma (13)C and unlabeled cis- and all-trans-lycopene concentrations. Although the bioavailability of cis (24.5% ± 6%) and all-trans (23.2% ± 8%) isomers did not differ, endogenous isomerization (0.97 ± 0.25 μmol/d in the fast-turnover tissue lycopene pool) drove tissue and plasma isomeric profiles. CONCLUSION: (13)C-Lycopene combined with physiologic compartmental modeling provides a strategy for following complex in vivo metabolic processes in humans and reveals that postabsorptive trans-to-cis-lycopene isomerization, and not the differential bioavailability of isomers, drives tissue and plasma enrichment of cis-lycopene. This trial was registered at clinicaltrials.gov as NCT01692340.
BACKGROUND:Lycopene, which is a red carotenoid in tomatoes, has been hypothesized to mediate disease-preventive effects associated with tomato consumption. Lycopene is consumed primarily as the all-trans geometric isomer in foods, whereas human plasma and tissues show greater proportions of cis isomers. OBJECTIVE: With the use of compartmental modeling and stable isotope technology, we determined whether endogenous all-trans-to-cis-lycopene isomerization or isomeric-bioavailability differences underlie the greater proportion of lycopene cis isomers in human tissues than in tomato foods. DESIGN: Healthy men (n = 4) and women (n = 4) consumed (13)C-lycopene (10.2 mg; 82% all-trans and 18% cis), and plasma was collected over 28 d. Unlabeled and (13)C-labeled total lycopene and lycopene-isomer plasma concentrations, which were measured with the use of high-performance liquid chromatography-mass spectrometry, were fit to a 7-compartment model. RESULTS: Subjects absorbed a mean ± SEM of 23% ± 6% of the lycopene. The proportion of plasma cis-(13)C-lycopene isomers increased over time, and all-trans had a shorter half-life than that of cis isomers (5.3 ± 0.3 and 8.8 ± 0.6 d, respectively; P < 0.001) and an earlier time to reach maximal plasma concentration than that of cis isomers (28 ± 7 and 48 ± 9 h, respectively). A compartmental model that allowed for interindividual differences in cis- and all-trans-lycopene bioavailability and endogenous trans-to-cis-lycopene isomerization was predictive of plasma (13)C and unlabeled cis- and all-trans-lycopene concentrations. Although the bioavailability of cis (24.5% ± 6%) and all-trans (23.2% ± 8%) isomers did not differ, endogenous isomerization (0.97 ± 0.25 μmol/d in the fast-turnover tissue lycopene pool) drove tissue and plasma isomeric profiles. CONCLUSION: (13)C-Lycopene combined with physiologic compartmental modeling provides a strategy for following complex in vivo metabolic processes in humans and reveals that postabsorptive trans-to-cis-lycopene isomerization, and not the differential bioavailability of isomers, drives tissue and plasma enrichment of cis-lycopene. This trial was registered at clinicaltrials.gov as NCT01692340.
Authors: Kati Fröhlich; Jürgen Conrad; Antje Schmid; Dietmar E Breithaupt; Volker Böhm Journal: Int J Vitam Nutr Res Date: 2007-11 Impact factor: 1.784
Authors: Nancy J Engelmann; Jessica K Campbell; Randy B Rogers; S Indumathie Rupassara; Peter J Garlick; Mary Ann Lila; John W Erdman Journal: J Agric Food Chem Date: 2010-09-22 Impact factor: 5.279
Authors: E Giovannucci; A Ascherio; E B Rimm; M J Stampfer; G A Colditz; W C Willett Journal: J Natl Cancer Inst Date: 1995-12-06 Impact factor: 13.506
Authors: A Heather Eliassen; Sara J Hendrickson; Louise A Brinton; Julie E Buring; Hannia Campos; Qi Dai; Joanne F Dorgan; Adrian A Franke; Yu-tang Gao; Marc T Goodman; Göran Hallmans; Kathy J Helzlsouer; Judy Hoffman-Bolton; Kerstin Hultén; Howard D Sesso; Anne L Sowell; Rulla M Tamimi; Paolo Toniolo; Lynne R Wilkens; Anna Winkvist; Anne Zeleniuch-Jacquotte; Wei Zheng; Susan E Hankinson Journal: J Natl Cancer Inst Date: 2012-12-06 Impact factor: 13.506
Authors: Elizabeth M Grainger; Steven J Schwartz; Shihua Wang; Nuray Z Unlu; Thomas W-M Boileau; Amy K Ferketich; J Paul Monk; Michael C Gong; Robert R Bahnson; Valerie L DeGroff; Steven K Clinton Journal: Nutr Cancer Date: 2008 Impact factor: 2.900
Authors: Nancy E Moran; Jennifer M Thomas-Ahner; Jessica L Fleming; Joseph P McElroy; Rebecca Mehl; Elizabeth M Grainger; Ken M Riedl; Amanda E Toland; Steven J Schwartz; Steven K Clinton Journal: J Nutr Date: 2019-03-01 Impact factor: 4.798
Authors: Joe L Rowles; Joshua W Smith; Catherine C Applegate; Rita J Miller; Matthew A Wallig; Amandeep Kaur; Jesus N Sarol; Salma Musaad; Steven K Clinton; William D O'Brien; John W Erdman Journal: J Nutr Date: 2020-07-01 Impact factor: 4.798
Authors: Joshua W Smith; Randy B Rogers; Sookyoung Jeon; Stanislav S Rubakhin; Lin Wang; Jonathan V Sweedler; Martha Neuringer; Matthew J Kuchan; John W Erdman Journal: Exp Biol Med (Maywood) Date: 2016-10-23
Authors: Besma Abbaoui; Christopher R Lucas; Ken M Riedl; Steven K Clinton; Amir Mortazavi Journal: Mol Nutr Food Res Date: 2018-08-29 Impact factor: 5.914
Authors: Nancy E Moran; Janet A Novotny; Morgan J Cichon; Kenneth M Riedl; Randy B Rogers; Elizabeth M Grainger; Steven J Schwartz; John W Erdman; Steven K Clinton Journal: J Nutr Date: 2015-12-16 Impact factor: 4.798
Authors: Christopher R D'Adamo; Antonietta D'Urso; Kathleen A Ryan; Laura M Yerges-Armstrong; Richard D Semba; Nanette I Steinle; Braxton D Mitchell; Alan R Shuldiner; Patrick F McArdle Journal: Nutrients Date: 2016-02-06 Impact factor: 5.717
Authors: R Andrew Shanely; David C Nieman; Penelope Perkins-Veazie; Dru A Henson; Mary P Meaney; Amy M Knab; Lynn Cialdell-Kam Journal: Nutrients Date: 2016-08-22 Impact factor: 5.717
Authors: Torsten Bohn; Charles Desmarchelier; Lars O Dragsted; Charlotte S Nielsen; Wilhelm Stahl; Ralph Rühl; Jaap Keijer; Patrick Borel Journal: Mol Nutr Food Res Date: 2017-02-27 Impact factor: 5.914